News

Anoro Ellipta is a combination of long-acting muscarinic antagonist (LAMA) and long-acting beta2-adrenergic agonist (LABA). The 24-week, blinded, parallel group, multicenter trial evaluated the efficacy and safety of

Embeda is used to manage pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. The updated label states that

EZH2 is a histone methyltransferase (HMT), which will play a potentially oncogenic role in a number of cancers such as germinal centre (GC) non-Hodgkin lymphomas, INI1-deficient cancers such

The drug has also been designated an orphan drug by the US Food and Drug Administration (FDA) to treat pancreatic cancer and small-cell lung cancer. The company claims

Granted marketing authorization under the trade-name Sovaldi in December 2013, Harvoni is a combination of the NS5A inhibitor ledipasvir and the nucleotide analog polymerase inhibitor sofosbuvir. The marketing

The company’s ANDA product is a generic version of Pfizer and Tris Pharma’s Quillivant XR, which is a central nervous system (CNS) stimulant indicated to treat attention deficit

Currently, OPS202 is evaluated in Phase I/II clinical trials and is based on a new next generation antagonistic somatostatin analog with improved receptor binding to sst2. The company

As part of the deal, Aduro will receive a $30m up-front payment and is also eligible to receive significant development, regulatory and commercialization milestone payments up to a

As part of the development, Sanofi Pasteur will contribute HSV-529, a clinical-stage replication-defective HSV vaccine product candidate, while Immune Design will provide its preclinical trivalent vaccine product candidate